Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and Wegovy, are expiring in nearly 100 nations.
Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended alongside a controlled diet and regular physical activity.
India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to transform access to weight-loss treatment.
Desperation for ‘weight-loss’ drug that’s used to treat type-2 diabetes is real. Break-ins at pharmacies have also been reported in Michigan, US, and Santiago de Copostela, Spain.
Weight-loss drugs helped Dimpy Kapoor shed 15 kg and reclaim her life. Ozempic and Mounjaro are a lifeline for diabetics and the obese, but everyone wants in—even those who don’t need them.
While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its effectiveness in obesity management come out in 3 months.
Health experts are now looking at whether semaglutide can also curb alcohol cravings among addicts. A look at how this GLP-1 category drug functions in humans.
Semaglutide mimics GLP-1 hormone released by gut after eating, which attaches itself to GLP-1 receptors in the body. Activated receptors help reduce blood sugar and curb appetite.
Central bank communication now holds as much significance as central bank action. A single clause in a press conference can move markets more than a 25-basis-point adjustment.
Order for 87 MALE drones will be split between 2 Indian firms in 64:36 ratio to ensure there are 2 independent manufacturing lines with at least 60% indigenous components.
The India-South Africa series-defining fact is the catastrophic decline of Indian red ball cricket where a visiting team can mock us with the 'grovel' word.
COMMENTS